ライフサイエンスコーパス: angiotensin I

1 h angiotensin II () as a substrate than with angiotensin I ().

2 activity was assessed by radioimmunoassay of angiotensin I.

3 brid, a resolution of 33,200 is achieved for angiotensin I.

4 d substrates with P1 Phe and does not cleave angiotensin I.

5 was preferred over [15N]10-microcystin-YR or angiotensin I.

6 For small peptides, such as angiotensin I (Agt I) and [Gln11]-amyloid-beta-protein f

7 The pressor response to exogenous angiotensin I (AI) was measured and normalized for the p

8 lysyl-proline (AcSDKP), urine AcSDKP, plasma angiotensin I (AI), plasma angiotensin II (AII), or the

9 lipid vesicle-bound angiotensin II (AII) and angiotensin I (AI).

10 with the use of brachial artery infusions of angiotensin I and angiotensin II at two doses, with and

11 oprotein of 120 kDa, which is able to cleave angiotensin I and angiotensin II but not bradykinin or H

12 sed by the differential vascular response to angiotensin I and angiotensin II.

13 activated neutrophils 1) converts both human angiotensin I and angiotensinogen to angiotensin II; 2)

14 atubular concentrations of AngII, as well as angiotensin I and angiotensinogen, are much greater than

15 ading capacities, approximately 100 fmol for angiotensin I and approximately 50 fmol for insulin, wer

16 acid, the known metal-binding amino acids of angiotensin I and bacitracin A are oxidized, while no ox

17 of cleaving the two hemoregulatory peptides angiotensin I and bradykinin, but differ in their affini

18 e, and a marked increase in constrictions to angiotensin I and II despite continuously increased plas

19 At this time, constrictions to angiotensin I and II were depressed, but there was no lo

20 nsinogen resulted in increased generation of angiotensin I and II.

21 cting peptides from physiological solutions, angiotensin I and insulin in artificial seawater are loa

22 iently extract two different peptides, human angiotensin I and MRFA, individually from an SDS contain

23 Unlabeled angiotensin I and porcine insulin are then deposited on

24 affinity for the 125I-radiolabeled peptides angiotensin I and porcine insulin.

25 r structural characterization/elucidation of angiotensin I and rapamycin is illustrated.

26 a peptidase responsible for the cleavage of angiotensin I and several other peptides.

27 recursor species such as multiply protonated angiotensin I and ubiquitin dissociated across a variety

28 oint of view is that the bioactive peptides, angiotensins I and II and vasoactive intestinal peptide,

29 Plasma renin and angiotensins I and II are undetectable.

30 nalysis of back-exchange in the decapeptide, angiotensin I, and a hexapeptide derived by digestion of

31 by CPA6, including Met- and Leu-enkephalin, angiotensin I, and neurotensin.

32 cter, antagonized the contractile effects of angiotensin I, and, importantly, caused a decrease in th

33 Several enzymes that hydrolyze angiotensin I (Ang I) and Ang II to Ang-(1-7) have been

34 se inhibitors on the contractile response to angiotensin I (Ang I) in human resistance arteries to in

35 duced vascular endothelial growth factor and angiotensin I (Ang I) production in RA ST fibroblasts an

36 is primarily known for its ability to cleave angiotensin I (Ang I) to the vasoactive octapeptide angi

37 In this study, Angiotensin I (ANG I) was directly injected into the SFO

38 Angiotensin I (Ang I) was generated from angiotensinogen

39 Six angiotensin I (Ang-I) variants were selected as model pe

40 med intrarenally from systemically delivered angiotensin I (AngI) and intrarenally formed AngI.

41 els of immunoreactive angiotensinogen (AGT), angiotensin I (AngI), and angiotensin II (AngII) were me

42 2-C12 tetra-alkyl ammonium ions, bradykinin, angiotensin I, angiotensin II, bovine ubiquitin, and two

43 tidyl 4-nitroanilides, and avidly hydrolyzes angiotensin I at Phe8 to generate bioactive angiotensin

44 pertrophy caused by a subpressor infusion of angiotensin is attenuated in mice deficient in the gp91p

45 giotensin-converting enzyme (ACE) can cleave angiotensin I, bradykinin, neurotensin and many other pe

46 te fluid homeostasis, cleaves the vasoactive angiotensin-I, bradykinin, and a number of other physiol

47 al effect of CNP on the vascular response to angiotensin I but not to angiotensin II suggest that CNP

48 system, we studied the enzymatic cleavage of angiotensin I by angiotensin converting enzyme and monit

49 bitor BILA 2157, which excludes formation of angiotensin I by proteases other than renin.

50 ssociation efficiencies for fragmentation of angiotensin I by resonance excitation are investigated a

51 Angiotensin I can be directly converted to angiotensin-(

52 )/cell; and 3) has similar high affinity for angiotensin I compared with free cathepsin G (Km = 5.9 x

53 in, and (3) stimulation of adrenal cortex by angiotensin is consistent with all the information avail

54 e of the most widely studied is the gene for angiotensin I converting enzyme (ACE ).

55 he angiotensin II (Ang II)-breakdown enzyme, angiotensin I converting enzyme (ACE) 2, suggests the im

56 shed Amadori ketoses showed moderate to weak angiotensin I converting enzyme (ACE) inhibitory activit

57 identify peptides with dual antioxidant and angiotensin I converting enzyme (ACE) inhibitory activit

58 Angiotensin I converting enzyme (ACE) inhibitory and ant

59 he activity of the peptide inhibitors of the angiotensin I converting enzyme (ACE), and the antiradic

60 othelin 1 (EDN1); we assayed the activity of angiotensin I converting enzyme (ACE), which catalyses t

61 The most hydrolysed sample showed high angiotensin I converting enzyme (ACE)-inhibitory and ant

62 Angiotensin I converting enzyme (kininase II; ACE) inhib

63 e N- and C-terminal domains of human somatic angiotensin I converting enzyme (sACE-1) demonstrate dis

64 ells expressing the SARS-CoV receptor, human angiotensin I converting enzyme 2 (hACE2).

65 II type 1 receptor antagonist (AT1RA) and/or angiotensin I converting enzyme inhibitor (ACEI) were in

66 Angiotensin-I converting enzyme (ACE) is a zinc dipeptid

67 Angiotensin-I converting enzyme (ACE) is a zinc metallop

68 egation analysis have shown that circulating angiotensin-I converting enzyme (ACE) levels are influen

69 Angiotensin-I converting enzyme (ACE), a two-domain dipe

70 An insertion polymorphism of the angiotensin-I converting enzyme gene (ACE) is common in

71 sweetness, bitterness and umami, as well as angiotensin-I converting enzyme inhibitory activity.

72 ddition to the extract's capacity to inhibit angiotensin I-converting enzyme (ACE) activity.

73 Using inhibitors of angiotensin I-converting enzyme (ACE) and CP, we show th

74 fraction of the heart and skeletal muscles, angiotensin I-converting enzyme (ACE) and neutral endope

75 g white, and (ii) evaluate the inhibition of angiotensin I-converting enzyme (ACE) by the obtained hy

76 n expended to determine whether the gene for angiotensin I-converting enzyme (ACE) confers susceptibi

77 The A-240T and I/D polymorphisms in the angiotensin I-converting enzyme (ACE) gene are markers o

78 Angiotensin I-converting enzyme (ACE) hydrolyzes numerou

79 Part of the beneficial effects of angiotensin I-converting enzyme (ACE) inhibitors are due

80 Angiotensin I-converting enzyme (ACE) inhibitors derived

81 To investigate how angiotensin I-converting enzyme (ACE) inhibitors enhance

82 Angiotensin I-converting enzyme (ACE) inhibitors have be

83 To investigate further the relationship of angiotensin I-converting enzyme (ACE) inhibitors to acti

84 es, majority of them were found identical to angiotensin I-converting enzyme (ACE) inhibitors, antiox

85 The angiotensin I-converting enzyme (ACE) inhibitory activit

86 The angiotensin I-converting enzyme (ACE) inhibitory activit

87 In addition, the effects of digestion on the angiotensin I-converting enzyme (ACE) inhibitory activit

88 hiols content but at the same time increased angiotensin I-converting enzyme (ACE) inhibitory activit

89 Angiotensin I-converting enzyme (ACE) inhibitory peptide

90 showed different amino acid compositions and angiotensin I-converting enzyme (ACE) inhibitory potenti

91 We determined the influence of angiotensin I-converting enzyme (ACE) insertion (I)/dele

92 Pedigree analyses have shown that angiotensin I-converting enzyme (ACE) levels are influen

93 Angiotensin I-converting enzyme (ACE), one of the centra

94 Although both LFHs <3 kDa showed in vitro angiotensin I-converting enzyme (ACE)-inhibitory activit

95 s established for oligopeptides that inhibit angiotensin I-converting enzyme (ACE).

96 ion (D) polymorphism (indel) of the gene for angiotensin I-converting enzyme (ACE).

97 Angiotensin I-converting enzyme (ACE)2, a new component

98 Angiotensin I-converting enzyme (ACE, or DCP1) is a zinc

99 Angiotensin I-converting enzyme (ACE, peptidyl dipeptida

100 eported previously a novel mode of action of angiotensin I-converting enzyme (kininase II; ACE) inhib

101 Human somatic angiotensin I-converting enzyme (sACE) has two active si

102 Human somatic angiotensin I-converting enzyme (sACE) is a key regulato

103 as associated with a significant decrease in angiotensin I-converting enzyme activity and a small, bu

104 pairs, we identified 91 that had discordant angiotensin I-converting enzyme and glutathione S-transf

105 nd an insertion/deletion polymorphism of the angiotensin I-converting enzyme gene (ACE) may be relate

106 These results confirm the association of the angiotensin I-converting enzyme indel with Alzheimer's d

107 amino groups, GABA content, antioxidant and angiotensin I-converting enzyme inhibitory (ACEI) activi

108 ffect on proteolysis and negatively affected angiotensin I-converting enzyme inhibitory activity of f

109 acids), bioactivity (antioxidant effect and angiotensin I-converting enzyme inhibitory activity), rh

110 y HRV only in the 20 participants using ACE (angiotensin I-converting enzyme) inhibitors.

111 system gene regions (angiotensinogen, renin, angiotensin I-converting enzyme, and angiotensin II rece

112 nst alpha-glucosidase, pancreatic lipase and angiotensin I-converting enzyme, using in vitro models.

113 inc metalloprotease whose closest homolog is angiotensin I-converting enzyme.

114 -binding proteins were identified as porcine angiotensin-I-converting enzyme (ACE I) and aminopeptida

115 work in animals suggests that inhibitors of angiotensin-I-converting enzyme (ACE) protect against ca

116 l phenotype [C1Inh, C4, spontaneous amidase, angiotensin-I-converting enzyme (ACE), aminopeptidase P

117 eutral endopeptidase (NEP, EC 3.4.24.11) and angiotensin-I-converting enzyme (ACE, EC 2.4.15.1), have

118 Angiotensin-I-converting enzyme (ACE-I) plays a key role

119 Angiotensin-I-converting enzyme activities were 58 (44-7

120 Inhibition of angiotensin is crucial in treatment of chronic kidney di

121 tidase that cleaves a single amino acid from angiotensin I, des-Arg bradykinin, and many other bioact

122 mast cell degranulation released enzyme with angiotensin I-forming activity blocked by the selective

123 The angiotensin I-forming activity of the renin protein was

124 al peptide hormones including bradykinin and angiotensin I have been described as substrates.

125 Angiotensin I, II, and III produced concentration-depend

126 Angiotensin I, II, and III; angiotensin-converting enzym

127 We determined the effect of angiotensin I, II, III, and IV and angiotensin-(1-7) on

128 he HDX rates for a small 10-residue peptide, angiotensin I, in aqueous droplets, from which we found

129 In response to chronic angiotensin I infusions, ACE 9/9 mice displayed increase

130 ward their receptors, CPA6 converts inactive angiotensin I into the biologically active angiotensin I

131 P1) is a zinc metallopeptidase that converts angiotensin I into the vasoactive and aldosterone-stimul

132 es were not effective for the enhancement of angiotensin I ions.

133 [Pro(11)(D)-Ala(12)] angiotensin I is an ACE-resistant substrate specific for

134 io (10-fold enhancement) in the detection of angiotensin I is demonstrated using the DRILL interface

135 nogen have normal fertility, indicating that angiotensin I is not a necessary substrate for testis AC

136 The best-known natural substrate, angiotensin I, is cleaved to generate vasoactive angiote

137 andards of polycyclic aromatic hydrocarbons, angiotensin I, lidocaine, ferrocene, diesel, and rosemar

138 cleavage of the peptide bond at proline for angiotensin I, Lys-bradykinin, and myoglobin are demonst

139 e state distributions was investigated using angiotensin I (M(r) = 1296), insulin (M(r) = 5774), and

140 ation of recombinant L-type Ca2+ channels by angiotensin is mediated by inositol trisphosphate-induce

141 in higher levels (16 +/- 6 versus 6 +/- 3 ng angiotensin I/ml per h, group 1 versus group 2, P = 0.01

142 old rats (13.9 +/- 3.8 versus 2.9 +/- 0.8 ng angiotensin I/ml per min), respectively.

143 onditions (1.3 +/- 0.2 versus 1.8 +/- 0.3 ng angiotensin I/ml per min).

144 amide), but did not display activity towards angiotensin I (NRVYIHPFHL), des-Arg bradykinin and AF1 (

145 ed to confirm intact deposition of [Val (5)]-Angiotensin I on a surface.

146 t significantly inhibit the effect of either angiotensin I or angiotensin II.

147 s for limit of detection was performed using angiotensin I peptide.

148 response to ACE inhibition (-0.4+/-0.4 ng of angiotensin I per milliliter per hour, as compared with

149 CNP inhibited the vasoconstrictive effect of angiotensin I (reduction in overall effect with CNP, 56.

150 ttomole detection limits of a model peptide (angiotensin I) spiked into a complex mixture (in this ca

151 d ACE2 activity toward its natural substrate angiotensin I, suggesting that they would be functional

152 Using a solution of angiotensin I, the carbon fiber emitter in 75-microm-i.d

153 is responsible for proteolytic activation of angiotensin I to angiotensin II (Ang II), a potent vasoc

154 y plasma proteinase inhibitors and converted angiotensin I to angiotensin II even in undiluted plasma

155 of serine proteases are enzymes that convert angiotensin I to angiotensin II, as well as others that

156 zyme (ACE) act by blocking the conversion of angiotensin I to angiotensin II, which is catalysed by t

157 hydrolyzes the carboxy terminal leucine from angiotensin I to generate angiotensin 1-9, which is conv

158 the carboxy terminal His-Leu dipeptide from angiotensin I to produce a potent vasopressor octapeptid

159 so known as ACE) catalyses the conversion of angiotensin I to the physiologically active peptide angi

160 ts to trigger the Ace2-to-Ace enzyme switch, angiotensin I-to-II conversion, and cardiac hypertrophy.

161 detection limit of 400 amol was achieved for angiotensin I using the nanofibrous carbon ME-SALDI subs

162 ion of fragments produced in the cleavage of angiotensin I was obtained using liquid chromatography-m

163 A solution of angiotensin I was quantified using this method, and the

164 total ion current peak areas of 500 fmol of angiotensin I were improved by a factor of 2.6 when the

165 rdiac myocytes produce increasing amounts of angiotensin I, which is converted to angiotensin II by t

166 ns accessible to small substrates, including angiotensin I, with activity in serum that is stable wit